Literature DB >> 3970041

Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort.

S Katusic, C M Beard, L T Kurland, J W Weis, E Bergstralh.   

Abstract

The medical records of all patients with rheumatoid arthritis diagnosed in Rochester, Minnesota, from 1950 to 1975 were examined to determine how many of them had malignant neoplasms. Follow-up averaged more than 14 years with outcome diagnoses complete in 98 percent of cases. All diagnoses of malignant neoplasm in this cohort were identified through the centralized record system based at the Mayo Clinic. Approximately 40 percent of these patients with rheumatoid arthritis were at least 60 years old at diagnosis. For comparison, the expected number of malignancies has been calculated using age-specific and site-specific rates from previous Rochester studies and the number of years of observation from date of diagnosis of rheumatoid arthritis to the date of last examination. Risk ratios have been calculated by dividing the observed number by the expected number of malignancies. Exact 95 percent confidence intervals around the risk ratios were calculated assuming that the observed number of cases has a Poisson distribution and that the expected number is fixed. Those patients with rheumatoid arthritis who had a malignancy before diagnosis have been analyzed separately, because they are at a higher risk. With the exception of multiple myeloma, no association was found between rheumatoid arthritis and subsequent cancer of any site.

Entities:  

Mesh:

Year:  1985        PMID: 3970041     DOI: 10.1016/0002-9343(85)90246-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  17 in total

Review 1.  Rheumatoid arthritis, malignancy, and paraproteins.

Authors:  C Kelly; H Sykes
Journal:  Ann Rheum Dis       Date:  1990-09       Impact factor: 19.103

2.  Non-Hodgkin's lymphoma in rheumatoid arthritis.

Authors:  D Porter; R Madhok; H Capell
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

3.  Light chain multiple myeloma in a patient with long-standing rheumatoid arthritis.

Authors:  Alexandra Alexopoulou; Spyros P Dourakis; Alexandra Apostolopoulou; Anna Kandyli; Helen Pandelidaki; Athanasios J Archimandritis
Journal:  Clin Rheumatol       Date:  2005-04-23       Impact factor: 2.980

4.  Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis.

Authors:  Stefanos Bonovas; Kalitsa Filioussi; Nikolaos M Sitaras
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

Review 5.  Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis: a case report and review of literature.

Authors:  Yasunobu Sekiguchi; Asami Shimada; Kunimoto Ichikawa; Mutsumi Wakabayashi; Keiji Sugimoto; Keigo Ikeda; Iwao Sekikawa; Shigeki Tomita; Hiroshi Izumi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ohta; Norio Komatsu; Masaaki Noguchi
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 6.  Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?

Authors:  L Georgescu; S A Paget
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 7.  Rational use of disease-modifying antirheumatic drugs.

Authors:  D E Furst
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

8.  Risk of cancer among rheumatoid arthritis patients in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2009-01-28       Impact factor: 2.506

9.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.

Authors:  Linda Morris Brown; Gloria Gridley; David Check; Ola Landgren
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

10.  A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs.

Authors:  L Klareskog; M Gaubitz; V Rodriguez-Valverde; M Malaise; M Dougados; J Wajdula
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.